Trials / Completed
CompletedNCT02206308
Safety, Pharmacokinetics and Pharmacodynamics of Recombinant Chimeric Anti-CD20 Monoclonal Antibody in Patients With B-cell Non-Hodgkin's Lymphoma.
A Phase I Dose Escalation Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SCT400, a Recombinant Chimeric Anti-CD20 Monoclonal Antibody，in Patients With CD20+ B-cell Non Hodgkin's Lymphoma.
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 15 (actual)
- Sponsor
- Sinocelltech Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine whether SCT400 is safe and effective in the treatment of B-cell Non Hodgkin's lymphoma
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Chimeric anti-CD20 monoclonal antibody |
Timeline
- Start date
- 2012-05-01
- Primary completion
- 2013-07-01
- Completion
- 2013-07-01
- First posted
- 2014-08-01
- Last updated
- 2014-08-01
Source: ClinicalTrials.gov record NCT02206308. Inclusion in this directory is not an endorsement.